



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

June 7, 2016

Intuit Medical, LLC  
Jack Griffis  
Vice President, Research & Development  
6018 Eagle's Rest Trail  
Sugar Hill, GA 30518

Re: K123264  
Trade/Device Name: DK-PTCA Balloon Catheter  
Regulation Number: 21 CFR 870.5100  
Regulation Name: Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter  
Regulatory Class: Class II  
Product Code: LOX  
Dated: October 17, 2012  
Received: October 18, 2012

Dear Mr. Griffis:

This letter corrects our substantially equivalent letter of January 16, 2013.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Kenneth J. Cavanaugh -S**

for  
Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

### Indications for Use

510(k) Number: K123264

Device Name: *DK-PTCA* Balloon Catheter

#### Indications for Use:

The Intuit Medical, LLC, *DK-PTCA* Balloon Catheter is indicated for balloon dilatation of the stenotic portion of coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of Cardiovascular Devices

Page 1 of 1

510(k) Number K123264



## 510(k) Summary

**510(k) Number:** K#123264

**JAN 16 2013**

**Date Prepared:** January 7<sup>th</sup>, 2013

This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92.

- A. **Submitter:**  
Intuit Medical, LLC  
6018 Eagle's Rest Trail  
Sugar Hill, Georgia 30518
- B. **Company Contact:**  
Jack Griffis  
Vice President, Research & Development  
(404) 583-6889 (direct)  
[jgriffis@intuitmedical.com](mailto:jgriffis@intuitmedical.com)
- C. **Device Information:**  
Trade Name: *DK-PTCA Balloon Catheter*  
Common Name: *Rapid Exchange Balloon Angioplasty Catheter*
- D. **Classification:** *Percutaneous Transluminal Coronary Angioplasty Catheter*  
*LOX, 21 CFR 870.5100(a)*
- E. **Predicate Device(s):**  
*Glider™ PTCA Balloon Catheter, K111544*  
*EMPIRA™ & EMPIRA™ NC Balloon Catheters, K110133*
- F. **Physical Description:**  
The DK-PTCA Balloon Catheter is a torqueable, rapid-exchange, percutaneous transluminal coronary angioplasty catheter. The device is compatible with commonly used accessories including standard 0.014" coronary guide wires and 6F guide catheters (MIN inner diameter of 0.074"). Catheter working length is approximately 142cm.
- The distal end of the catheter has a semi-compliant balloon that expands to known diameters and lengths at specific pressures. The balloon has two radiopaque markers to assist with positioning. The proximal end of the device is a common PTCA catheter design consisting of a hypo-tube connected to a plastic hub and strain relief and which assists with torque transmission. The hub is used to inflate the balloon and the luer connector is compatible with standard inflation devices. A second lumen within the catheter, intended for guidewire use, extends from the rapid exchange port to the distal tip. The DK-PTCA Balloon Catheter is supplied sterile and intended for single use.

G. Indications for Use:

The DK-PTCA Balloon Catheter is indicated for balloon dilatation of the stenotic portion of coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.

H. Comparison of Characteristics / Performance Testing / Substantial Equivalence:

The DK-PTCA Balloon Catheter is substantially equivalent to the predicate devices in intended use, indications for use, fundamental scientific technology, and important performance specifications. The device was subjected to the following performance tests according to FDA Guidance *Class II Special Controls for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters* (September 8, 2010):

- Dimensional Verification
- Balloon Preparation, Deployment & Retraction
- Flexibility & Kink
- Balloon Rated Burst Pressure (RBP)
- Balloon Fatigue
- Balloon Compliance
- Balloon Inflation and Deflation
- Catheter Bond Strength
- Tip Pull Test
- Torque Strength
- Radiopacity
- Biocompatibility Testing in Compliance with the ISO 10993-1 and the FDA Bluebook Memorandum (G-95)
  - Cytotoxicity
  - Sensitization (Guinea Pig Maximization)
  - Irritation and (Acute) Systemic Toxicity
  - Hemocompatibility (both complement activation and *in-vivo* thrombo-resistance)
  - Genotoxicity
  - Material-mediated Pyrogenicity

No new questions of safety or effectiveness were identified during device testing; therefore, the DK-PTCA Balloon Catheter is considered substantially equivalent to the predicate devices.

---

Jack Griffis  
Vice President, Research & Development



6018 Eagle's Rest Trail  
Sugar Hill, GA 30518  
404-583-6889 phone  
jgriffis@intuitmedical.com